Iberdomide
As of the edition of 20 October 2026, Iberdomide is a small molecule: marketed, first approved in 2026 (US); acts on CRBN, CUL4A and DDB1 and 1 more; US protection ends in 2031.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Zenbexus
- First approved
- 13 August 2026 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Bristol Myers Squibb
- Registered trials
- 54, 5 stopped early
- Disease areas
- Immune system; Cancer; Blood and lymph; Heart and blood vessels; Skin and connective tissue; Inherited and neonatal
US protection
US protection ends in 2031.
The last listed US exclusivity ends in 2031. The application that gives this date is held by Bristol Myers Squibb.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 20 | 8 | 9 | 3 |
| Phase 2 | 28 | 3 | 20 | 2 |
| Phase 3 | 5 | 0 | 5 | 0 |
| All trials | 54 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Originator and Lead sponsor of trials | 2012 to now |